Información del artículo
Resumen
La psoriasis es una enfermedad crónica, que cursa por brotes, y que en un momento determinado de su evolución, o en ciertos pacientes, puede afectar una gran parte de la superficie corporal con graves repercusiones físicas y psíquicas. Los tratamientos utilizados en este tipo de pacientes se asocian a múltiples efectos secundarios y requieren numerosos controles clínicos y analíticos.
La aparición de las nuevas terapias biológicas en el arsenal terapéutico del dermatólogo ha aportado numerosas ventajas para el control y mantenimiento del paciente psoriásico. La facilidad de uso, limpieza, comodidad posológica y sencillez de su manejo han cambiado la perspectiva de la enfermedad. Su eficacia parece comparable o superior a la conseguida por terapias sistémicas clásicas como la fototerapia, los retinoides, metotrexato o ciclosporina.
Presentamos un caso clínico de psoriasis grave, que presentó una rápida y completa respuesta a etanercept. A propósito del mismo realizamos un revisión bibliográfica dirigida a los aspectos de seguridad y eficacia a corto plazo –menos de 12 semanas de tratamiento– en pacientes psoriásicos tratados con esta molécula.
Palabras clave:
Psoriasis
Etanercept
Eficacia
Seguridad
Abstract
Psoriasis is a chronic disease that occurs in episodes and which, in a certain moment of its evolution or in some patients, may affect a large portion of the body surface with serious physical and psychological repercussions. The treatment used in this type of patient is associated to many side effects and requires numerous clinical and laboratory controls.
The appearance of the new biological therapies in the therapeutic armamentum of the dermatologist has provided many advantages for the control and maintenance of the psoriatic patient. Their ease of use, cleanliness, dose comfort and ease-of-management have changed the patient's perspective. Their efficacy seems to be comparable or superior to those achieved by the classical systemic therapies such as phototherapy, retinoids, methotrexate or cyclosporine.
We present a clinical case of severe psoriasis that presented a rapid and complete response to etanercept. Based on this case, we performed a bibliographic review aimed at the short-term safety and efficacy aspects, less than 12 weeks of treatment, in psoriatic patients treated with this molecule.
Keywords:
Psoriasis
Etanercept
Efficacy
Safety
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, B.S. Goffe, et al.
A randomized trial of etanercept as monotherapy for psoriasis.
Arch Dermatol, 139 (2003), pp. 1627-1632
[2.]
C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, A. Wang, et al.
Etanercept as monotherapy in patients with psoriasis.
N Engl J Med, 349 (2003), pp. 2014-2022
[3.]
K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, et al.
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Br J Dermatol, 152 (2005), pp. 1304-1312
[4.]
K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, A. Jahreis, et al.
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
J Dermatolog Treat, 17 (2006), pp. 9-17
[5.]
S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, A. Wang, et al.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
Lancet, 367 (2006), pp. 29-35
[6.]
Daudén E, Griffi ths C, Ortonne JP, Kragballe K, Molta C, Robertson D, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009 (en prensa).
[7.]
P.C. Van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, A. Kaszuba, et al.
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate- to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
Br J Dermatol, 159 (2008), pp. 1177-1185
[8.]
A. Moore, K.B. Gordon, S. Kang, A. Gottlieb, B. Freundlich, H.A. Xia, et al.
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
J Am Acad Dermatol, 56 (2007), pp. 598-603
[9.]
R. Jiménez-Puya, F. Gómez-García, V. Amorrich-Campos, J.C. Moreno- Giménez.
Etanercept: efficacy and safety.
J Eur Acad Dermatol Venereol, 23 (2009), pp. 402-405
[10.]
A.S. Paller, E.C. Siegfried, R.G. Langley, A.B. Gottlieb, D. Pariser, I. Landells, et al.
Etanercept treatment for children and adolescents with plaque psoriasis.
N Engl J Med, 358 (2008), pp. 241-251
[11.]
W.H. Boehncke, R.A. Brasie, J. Barker, S. Chimenti, E. Daudén, M. de Rie, et al.
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus.
J Eur Acad Dermatol Venereol, 20 (2006), pp. 988-998
[12.]
J.M. Casanova, V. Sanmartín, R.M. Martí, M. Ferrán, R.M. Pujol, M. Ribera.
Tratamiento de la psoriasis en placas moderada y grave con etanercept.
Piel, 24 (2009), pp. 105-113
[13.]
B. Goffe, J.C. Cather.
Etanercept: an overview.
J Am Acad Dermatol, 49 (2003), pp. S105-S111
[14.]
A. Romero-Mate, C. García-Donoso, S. Córdoba-Guijarro.
Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review.
Am J Clin Dermatol, 8 (2007), pp. 143-155
[15.]
R. Zeltser, L. Valle, C. Tanck, M.M. Holyst, C. Ritchlin, A.A. Gaspari.
Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.
Arch Dermatol, 137 (2001), pp. 893-899
[16.]
A.B. Gottlieb, C.L. Leonardi, B.S. Goffe, J.P. Ortonne, P.C. van der Kerkhof, R. Zitnik, et al.
Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
J Am Acad Dermatol, 54 (2006), pp. S92-S100
[17.]
S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, M. Dunn, et al.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Arch Dermatol, 143 (2007), pp. 719-726
[18.]
B. Killingley, V. Carpenter, K. Flanagan, G. Pasvol.
Pneumococcal meningitis and etanercept-chance or association?.
J Infect, 51 (2005), pp. E49-51
[19.]
N. Maimon, J. Brunton, A.K. Chan, T.K. Marras.
Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.
Thorax, 62 (2007), pp. 739-740
[20.]
M.J. Kang, M.S. Kim, E.H. Choi, K.E. Lee, Y.K. Kim, H.J. Choi.
Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis.
Korean J Intern Med, 22 (2007), pp. 63-66
[21.]
J.K. Hoang, J. Burruss.
Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy.
Pediatr Dermatol, 24 (2007), pp. 285-288
[22.]
J. Bourre-Tessier, C. Fortin, A. Belisle, E. Desmarais, D. Choquette, J.L. Senecal.
Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept.
Scand J Rheumatol, (2009), pp. 1-6
[23.]
G. Schett, P. Herak, W. Graninger, J.S. Smolen, M. Aringer.
Listeriaassociated arthritis in a patient undergoing etanercept therapy: case report and review of the literature.
J Clin Microbiol, 43 (2005), pp. 2537-2541
[24.]
F. Tubach, P. Ravaud, D. Salmon-Ceron, N. Petitpain, O. Brocq, F. Grados, et al.
Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.
Clin Infect Dis, 43 (2006), pp. e95-e100
[25.]
J.L. Sánchez Carazo, L. Mahiques Santos, V. Oliver Martínez.
Safety of etanercept in psoriasis: a critical review.
Drug Saf, 29 (2006), pp. 675-685
[26.]
F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille, M. Breban, et al.
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry.
Arthritis Rheum, 60 (2009), pp. 1884-1894
[27.]
W. Sumner, S.R. Feldman.
Conversion to positive tuberculosis test during etanercept treatment of psoriasis.
J Drugs Dermatol, 6 (2007), pp. 1048
[28.]
J.J. Gómez-Reino, L. Carmona, M. Ángel Descalzo.
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Arthritis Rheum, 57 (2007), pp. 756-761
[29.]
A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, N.J. Korman, et al.
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
J Am Acad Dermatol, 58 (2008), pp. 1031-1042
[30.]
A. Gottlieb, N.J. Korman, K.B. Gordon, S.R. Feldman, M. Lebwohl, J.Y. Koo, et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
J Am Acad Dermatol, 58 (2008), pp. 851-864
[31.]
S.D. Doherty, A. Van Voorhees, M.G. Lebwohl, N.J. Korman, M.S. Young, S. Hsu, et al.
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
J Am Acad Dermatol, 59 (2008), pp. 209-217
[32.]
R.S. Wallis, P. Kyambadde, J.L. Johnson, L. Horter, R. Kittle, M. Pohle, et al.
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.
AIDS, 18 (2004), pp. 257-264
[33.]
S. Domm, J. Cinatl, U. Mrowietz.
The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
Br J Dermatol, 159 (2008), pp. 1217-1228
[34.]
P.T. Ting, J.Y. Koo.
Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients.
Int J Dermatol, 45 (2006), pp. 689-692
[35.]
E.J. Cepeda, F.M. Williams, M.L. Ishimori, M.H. Weisman, J.D. Reveille.
The use of anti-tumour necrosis factor therapy in HIVpositive individuals with rheumatic disease.
Ann Rheum Dis, 67 (2008), pp. 710-712
[36.]
M. Mikhail, J.M. Weinberg, B.L. Smith.
Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
Arch Dermatol, 144 (2008), pp. 453-456
[37.]
P.P. Kaur, V.C. Chan, S.N. Berney.
Successful etanercept use in an HIV-positive patient with rheumatoid arthritis.
J Clin Rheumatol, 13 (2007), pp. 79-80
[38.]
C. Giannitti, M. Benucci, R. Caporali, S. Manganelli, F. Bellisai, G.D. Sebastiani, et al.
Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection.
Int J Immunopathol Pharmacol, 22 (2009), pp. 543-546
[39.]
I. Cavazzana, A. Ceribelli, R. Cattaneo, F. Franceschini.
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.
Autoimmun Rev, 8 (2008), pp. 104-106
[40.]
Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW 3rd, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol. 2009 (en prensa).
[41.]
P.M. Montiel, J.A. Solis, J.A. Chirinos, B. a Casis, F. Sánchez, S. Rodríguez.
Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.
Liver Int, 28 (2008), pp. 718-720
[42.]
S.B. Desai, D.E. Furst.
Problems encountered during antitumour necrosis factor therapy.
Best Pract Res Clin Rheumatol, 20 (2006), pp. 757-790
[43.]
M.B. Carroll, M.I. Bond.
Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Semin Arthritis Rheum, 38 (2008), pp. 208-217
[44.]
M. Benucci, M. Manfredi, L. Mecocci.
Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepa titis B.
J Clin Rheumatol, 14 (2008), pp. 245-246
[45.]
R.V. Patel, L.N. Clark, M. Lebwohl, J.M. Weinberg.
Treatments for psoriasis and the risk of malignancy.
J Am Acad Dermatol, 60 (2009), pp. 1001-1017
[46.]
J. Listing, A. Strangfeld, J. Kekow, M. Schneider, A. Kapelle, S. Wassen berg, et al.
Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?.
Arthritis Rheum, 58 (2008), pp. 667-677
[47.]
S.A. Sukal, L. Nadiminti, R.D. Granstein.
Etanercept and demyelinating disease in a patient with psoriasis.
J Am Acad Dermatol, 54 (2006), pp. 160-164
[48.]
A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, K.B. Gordon, et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
J Am Acad Dermatol, 58 (2008), pp. 826-850
[49.]
E. Tobinick.
Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence.
CNS Drugs, 23 (2009), pp. 713-725
[50.]
M. Dinomais, L. Stana, G. Egon, I. Richard, P. Menei.
Significant recovery of motor function in a patient with complete T7 paraplegia receiving etanercept.
J Rehabil Med, 41 (2009), pp. 286-288
[51.]
Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2009 (en prensa).
[52.]
R.K. Dore, S. Mathews, J. Schechtman, W. Surbeck, D. Mandel, A. Patel, et al.
The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.
Clin Exp Rheumatol, 25 (2007), pp. 40-46
[53.]
M.F. Costa, N.R. Said, B. Zimmermann.
Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
Semin Arthritis Rheum, 37 (2008), pp. 381-387
[54.]
S. Bout-Tabaku, R. Rivas-Chacon, R. Restrepo.
Systemic lupus erythematosus in a patient treated with etanercept for poly articular juvenile rheumatoid arthritis.
J Rheumatol, 34 (2007), pp. 2503-2504
[55.]
S. Exarchou, P. Voulgari, T. Markatseli, A. Zioga, A. Drosos.
Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Scand J Rheumatol, (2009), pp. 1-4
[56.]
I. Lahbabi, H. Adamski, S. Le Jean, V. Cannieux, E. Polard, J. Chevrant-Breton.
Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept.
Ann Dermatol Venereol, 135 (2008), pp. 409-410
[57.]
J. Kuruvilla, H.A. Leitch, L.M. Vickars, P.F. Galbraith, C.H. Li, S. Al-Saab, et al.
Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.
Eur J Haematol, 71 (2003), pp. 396-398
[58.]
C. Dufour, R. Giacchino, P. Ghezzi, R. Tonelli, E. Ferretti, A. Pitto, et al.
Etanercept as a salvage treatment for refractory aplastic anemia.
Pediatr Blood Cancer, 52 (2009), pp. 522-525
Copyright © 2010. Academia Española de Dermatología y Venereología
